Результаты поиска

Plasmablastic lymphoma of the oral cavity with breast recurrence: a case report.

BackgroundPlasmablastic lymphoma is an aggressive variant of diffuse large B cell lymphoma, mostly found in the oral cavity and associated with human immunodeficiency virus. There are no clear guidelines for its treatment. Therapies more intensive than cyclophosphamide, doxorubicin, vincristine, and prednisone are not associated with a prolonged survival. Lymphomas of the breast are rare, in one series representing 0.14% of all female breast malignancies, with diffuse large B cell lymphoma comprising up to 55% of all cases. Only one case of plasmablastic lymphoma involving the breast has been

Precision Medicine Through Network Language: Integrating Clinical Insight and Data Expertise.

Precision medicine is facing a critical transition driven by the growing complexity of biological data and the insufficient ability of current models to translate such data into clinically meaningful information. Linear, single-gene approaches are no longer adequate to explain the multifactorial nature of most modern diseases, whose phenotypes emerge from combinations of genetic, molecular, and environmental factors. Network-based precision medicine addresses this by providing a systemic framework capable of integrating heterogeneous omics data, interactomes, and clinical information to identi

Совпадение в полном тексте источника
… The oncologist or general practitioner is thus faced with complex, sometimes ambiguous information that is difficult to integrate with the patient’s overall clinical picture, comorbidities, guidelines and therapeutic options available. … MTBs are multidisciplinary teams composed of oncologists, molecular pathologists, bioinformaticians, geneticists and other experts whose main task is to provide genomically informed clinical recommendations for cases with complex alterations. …

Измеряемое остаточное заболевание гематологовых магнатов: биомаркер в поисках стандарта.

За последнее десятилетие измеримые остаточные заболевания (МРД) стали важнейшим инструментом обнаружения и мониторинга различных раковых заболеваний, но особенно гематологовых заболеваний. Быстрая адаптация этого новаторского подхода к мониторингу состояния заболеваний является интуитивно привлекательной: он обеспечивает значительно большую чувствительность по сравнению с традиционными методами обнаружения небольшого числа злокачественных клеток, которые сохраняются после лечения и которые не поддаются обнаружению с помощью таких стандартных подходов, как мониторинг аномалий на рентгенографиче

Совпадение в полном тексте источника
… Attitudes and perspectives of oncologists about measurable residual disease testing in multiple myeloma: initiative for standardizing guidelines. Bone Marrow Transplant. 2025 doi: 10.1038/s41409-025-02604-3. 79. Dawkins M.D., El Chaer F., Boehmer L., et al. … MM-318 perspectives of single-center community hematologists/oncologists on minimal residual disease testing among patients with multiple myeloma. Clin Lymphoma Myeloma Leuk. 2024;24 …

Enabling exercise prescription for survivors of cancer.

Although exercise is widely recommended for survivors of cancer, readily implementable approaches for evaluating exercise tolerance enabling exercise prescriptions at appropriate levels of cardiovascular exertion are not always available. We evaluated the utility of modified Harvard Step tests within the context of a standard physical examination for fitness evaluation and exercise prescription for survivors of cancer across a range of age, BMI and exercise history. While 52% of presenting individuals with a past cancer diagnosis were able to complete a 3-min test at pace with a reduced 9-in.

From Osteoclast Differentiation to Osteonecrosis of the Jaw: Molecular and Clinical Insights.

Bone physiology relies on the delicate balance between resorption and formation of its tissue. Bone resorption depends on a process called osteoclastogenesis in which bone-resorbing cells, i.e., osteoclasts, are produced by the differentiation of more undifferentiated progenitors and precursors. This process is governed by two main factors, monocyte colony-stimulating factor (M-CSF) and receptor activator of NFκB ligand (RANKL). While the former exerts a proliferating effect on progenitors/precursors, the latter triggers a differentiation effect on more mature cells of the same lineage. Bone h

Совпадение в полном тексте источника
… Discontinuation of intravenous BPs and subcutaneous DMAb may be considered by oncologists [ 74 ]. However, no data are available for supporting the effectiveness of secession of intravenous BPs and subcutaneous DMAb on the prevention of ONJ. … Oncologist 2012 17 1114 1119 10.1634/theoncologist.2012-0141 22723507 PMC3425530 85. Priemel M. von Domarus C. Klatte T.O. Kessler S. Schlie J. Meier S. Proksch N. Pastor F. Netter C. Streichert T. …

The Evolving Landscape of Immune Regulation and Immunotherapy in Cholangiocarcinoma and Biliary Tract Cancer.

Cholangiocarcinoma (CCA) is an aggressive and molecularly heterogeneous malignancy characterized by a profoundly immunosuppressive tumor microenvironment (TME) and historically limited therapeutic options. Recent advances have redefined the treatment paradigm, with phase III trials establishing chemoimmunotherapy as a standard of care and multi-omic profiling elucidating the interplay between tumor genomics, stromal architecture, and immune regulation. Despite these gains, durable clinical benefit remains confined to a minority of patients, reflecting convergent mechanisms of primary and acqui

The contribution of spirituality and religiousness to the quality of life of cancer patients treated with radiotherapy in Ghana: a cross-sectional study.

Cancer is one of the leading causes of morbidity and mortality globally. A significant proportion of all patients with cancer require radiotherapy as part of their treatment. Cancer can be very terrifying for patients undergoing radiotherapy, especially when it undermines their ability to hope or cope. In Ghana, where religious and spiritual beliefs play a significant role in many individuals' lives, understanding how these factors affect patients' well-being during cancer treatment is crucial. This study examined the contribution of spirituality and religiousness to the quality of life (QoL)

Совпадение в полном тексте источника
… “When the doctors (radiation oncologists) demonstrate respect for my religious practices, like praying and reading “healing psalms” before treatment, it makes me feel more confident that I’m in good hands.” … Oncologist assisted spiritual intervention study (OASIS): patient acceptability and initial evidence of effects. Int J Psychiatry Med. 2005;35(4):329–347. doi: 10.2190/8AE4-F01C-60M0-85C8. 30. Rodrigues-Sobral MM, Carneiro L, Pupe CC, et al. …

A discrete choice experiment analysis to understand patient preferences for multiple myeloma treatments.

IntroductionMultiple myeloma (MM) is a malignant plasma cell disorder characterized by the clonal expansion of abnormal plasma cells within the bone marrow. The management of relapsed/refractory multiple myeloma (RRMM) represents a significant challenge as the disease relapses or becomes refractory to previous treatments. Recent advances in therapy have expanded RRMM treatment options. This study aimed to gain a deeper understanding of patients' treatment preferences regarding available therapeutic options.MethodsThis study was designed as a non-interventional descriptive cross-sectional study

Neurosurgical management of brain metastases in the elderly: a prospective study on adverse event prevalence and predictors.

The management of brain metastases (BM) in geriatric patients poses significant challenges in the context of an aging population and advances in systemic cancer treatment. This study provides insights into the prevalence and nature of adverse events (AEs) following intracranial surgery in patients aged 65 years and older. It highlights the complexities and implications of treating this demographic patient population and identifies risk factors associated with AEs. This prospective study includes patients aged 65 years and older with BM who underwent surgery between January 2022 and December 20

Совпадение в полном тексте источника
… Procedures In this study, each patient’s treatment plan was discussed in a multidisciplinary tumor board comprising neurosurgeons, medical oncologists, radiation oncologists, and palliative care specialists. …

Trend and burden of adult cancer-related hospitalizations in the United States.

To calculate national trends and estimates of cancer-related hospitalizations, hospital outcomes, and hospitalization costs. The current study was a retrospective analysis of National Inpatient Sample data, collected during 2008 to 2019. Adult cancer hospitalizations were identified by Clinical Classifications Software codes. We estimated weighted frequencies, proportions, and trends in cancer-related hospitalizations, hospital outcomes, and hospitalization costs. The primary outcome of the study was cancer-related hospitalizations, and secondary outcomes were the reasons for hospitalization,

Совпадение в полном тексте источника
… In addition, interventions to decrease avoidable cancer hospitalization should not affect the therapeutic relationship between patient and oncologist and patient-centered cancer care. … Oncologists and other specialists could incorporate coordinated care approaches to effectively assess and manage comorbidities in outpatient settings to decrease unnecessary hospitalizations. …

Cancer burden across the South Asian Association for Regional Cooperation in 2022.

ObjectiveThe objective of this study is to present a cross-sectional analysis of cancer burden in the South Asian Association for Regional Cooperation (SAARC) region and explain unique characteristics of its cancer burden as compared with the rest of the world.Methods and analysisUsing publicly available data from the Global Cancer Observatory (GCO) and the World Bank, we collected cancer statistics and population statistics for Afghanistan, Bangladesh, Bhutan, India, the Maldives, Nepal, Pakistan, and Sri Lanka from 2017 to 2022.ResultsThe number of newly diagnosed cases in the region was 1 8

Совпадение в полном тексте источника
… Bhutan also lacks sufficient radiation oncologists and medical oncologists, leaving surgeons in various fields to serve at the forefront of managing patients with cancer. …

Роль питания и кишечного микробиома в развитии множественной миеломы и ее болезней-прекурсоров.

Множественная миелома (ММ) — вторая по распространенности гематологическая гелингология, характеризующаяся нерегулируемым моноклонным распространением в костном мозге. Моноклональная гаммопатия неопределённого значения (MMUS) и мрачная миелома (SMM) являются предмалярными условиями, которые могут развиваться до MM. Определение факторов этиологического риска для ММ и его болезней-прекурсоров имеет решающее значение для профилактики. Ожирение, питание, уровень витамина D и изменение кишечного микробиота были определены в качестве факторов образа жизни, влияющих на риск MM и MGUS. При возникновен

Validation of a scale to assess adherence to oral chemotherapy based on the experiences of patients and healthcare professionals (EXPAD-ANEO).

Background: Lack of adherence to Oral antineoplastic agents (OAAs) treatment has important clinical, social and economic consequences. Objective: To develop and validate a novel instrument for assessing adherence to OAAs, based on the reported experiences of people with cancer in relation to their treatment and the opinions of the healthcare professionals who care for them. Methods: We performed a multicenter validation study of a scale designed to assess adherence to OAAs. First, a steering committee developed the items for an initial scale, based on the results of a qualitative study that ev

Совпадение в полном тексте источника
… For this panel, we recruited eight people through purposive sampling ( Otzen and Manterola, 2017 ): four were healthcare professionals (two medical oncologists and two pharmacists) with at least 5 years of experience in cancer management, treatment and research; and four were people with cancer who had … Two professionals were oncologists and two were pharmacists. The average age of the professionals was 46 (SD 9) years, and one was a woman. Half of respondents thought the scale was understandable, while the rest suggested removing the abbreviations and changing the wording of items 2, 5, 7 and 17. …

ProTarget: a Danish Nationwide Clinical Trial on Targeted Cancer Treatment based on genomic profiling - a national, phase 2, prospective, multi-drug, non-randomized, open-label basket trial.

BackgroundAn increasing number of trials indicate that treatment outcomes in cancer patients with metastatic disease are improved when targeted treatments are matched with druggable genomic alterations in individual patients (pts). An estimated 30-80% of advanced solid tumors harbor actionable genomic alterations. However, the efficacy of personalized cancer treatment is still scarcely investigated in larger, controlled trials due to the low frequency and heterogenous distribution of druggable alterations among different histologic tumor types. Therefore, the overall effect of targeted cancer

Совпадение в полном тексте источника
… Many oncologists and pathologists have sparse access to comprehensive genomic profiling for screening purposes and experts for interpretation of genomic test reports to guide scientifically informed decisions about the optimal use of targeted agents [ 9 ]. … The DN-MTB plays a pivotal role in ProTarget; this national, multidisciplinary collaboration is attended by oncologists, molecular biologists, bioinformaticians, pathologists, and clinical geneticists from eight centers across Denmark covering 5.7 million inhabitants. …

A Phase I First-in-Human Study of ABBV-383, a B-Cell Maturation Antigen × CD3 Bispecific T-Cell Redirecting Antibody, in Patients With Relapsed/Refractory Multiple Myeloma.

PurposeABBV-383, a B-cell maturation antigen × CD3 T-cell engaging bispecific antibody, has demonstrated promising results in an ongoing first-in-human phase I study (ClinicalTrials.gov identifier: NCT03933735) in patients with relapsed/refractory multiple myeloma (RRMM). Herein, we report safety and efficacy outcomes of this phase I dose escalation/expansion study.MethodsPatients with RRMM (≥ three prior lines including a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 monoclonal antibody) were eligible. ABBV-383 was administered intravenously over 1-2 hours once every 3 week

Pomalidomide plus dexamethasone for patients with relapsed or refractory multiple myeloma: Final results of the non-interventional study POSEIDON and comparison with the pivotal phase 3 clinical trials.

BACKGROUND: Prognosis of patients with multiple myeloma (MM) who have relapsed on or become refractory to immunomodulators and bortezomib is poor, and treatment options are limited. While pomalidomide plus low-dose dexamethasone (POM/DEX) has demonstrated efficacy in clinical trials, real-world evidence is scarce. PATIENTS AND METHODS: POSEIDON was a prospective non-interventional study designed to evaluate effectiveness, safety and quality of life (QoL) of POM/DEX in patients with relapsed or refractory MM (R/RMM) pretreated with at least two prior therapy lines including both lenalidomide a

Совпадение в полном тексте источника
… Patients were enrolled between 2014 and 2017 at 43 study sites across Germany including hemato‐oncologists in hospitals and outpatient clinics, and independent oncology practices. Patients were recruited into two cohorts (I/II) stratified by last prior treatment line. … Henning Eschenburg: HONORARIA: Workshop for oncologists in cooperation with Roche AG. AUTHOR CONTRIBUTIONS T. Dechow, S. Grebhardt, C. Vannier and K. Potthoff were involved in conceptualization and design. T. Dechow, A. Aldaoud, T. Behlendorf, W. Knauf, H. Eschenburg, M. Groschek, R. …

Review of Myeloma Therapies and Their Potential for Oral and Maxillofacial Side Effects.

Myeloma is a common haematological malignancy in which adverse skeletal related events are frequently seen. Over recent years, treatment for myeloma has evolved leading to improved survival. Antiresorptive therapy is an important adjunct therapy to reduce the risk of bone fractures and to improve the quality of life for myeloma patients; however, this has the potential for unwanted side effects in the oral cavity and maxillofacial region. Osteonecrosis of the jaw related to antiresorptive medications and other myeloma therapies is not uncommon. This review serves to highlight the risk of osteo

Совпадение в полном тексте источника
… Although uncommon, MRONJ is in fact not a rare adverse event in myeloma patients; therefore, continuous monitoring and vigilance is essential from haemato-oncologists, and dental and oral maxillofacial specialists [ 2 ]. Treatment for MRONJ depends on its severity and clinical signs and symptoms. … Currently, there is limited evidence for initiating a ‘drug holiday’ prior to performing invasive dental procedures; however, this should be discussed with the haemato-oncologist and decided on in a case-by-case basis [ 53 ]. …

Medication-Related Osteonecrosis of Jaws (MRONJ) Prevention and Diagnosis: Italian Consensus Update 2020.

The Medication-Related Osteonecrosis of Jaws (MRONJ) diagnosis process and its prevention play a role of great and rising importance, not only on the Quality of Life (QoL) of patients, but also on the decision-making process by the majority of dentists and oral surgeons involved in MRONJ prevention (primary and secondary). The present paper reports the update of the conclusions from the Consensus Conference-held at the Symposium of the Italian Society of Oral Pathology and Medicine (SIPMO) (20 October 2018, Ancona, Italy)-after the newest recommendations (2020) on MRONJ were published by two s

Совпадение в полном тексте источника
… Drug Holiday or Temporary Suspension for Patients at Risk of MRONJ: Practices at Risk of Inappropriateness and Good Practices Assuming that a drug holiday is a controversial issue, involving both drug prescribers (oncologists, hematologists, bone health specialists and general practitioners) and oral … Questionable Practices (#1) Performing dental extraction or oral surgery in patients with active cancer and myeloma bone disease and in therapy with i.v. high-dose bisphosphonates or denosumab (Xgeva ® ) without agreeing any temporary suspension with the prescriber (oncologist/hematologist). (#2) Suspending …

Long-term survival, prevalence, and cure of cancer: a population-based estimation for 818 902 Italian patients and 26 cancer types.

BackgroundPersons living after a cancer diagnosis represent 4% of the whole population in high-income countries. The aim of the study was to provide estimates of indicators of long-term survival and cure for 26 cancer types, presently lacking.Patients and methodsData on 818 902 Italian cancer patients diagnosed at age 15-74 years in 1985-2005 were included. Proportions of patients with the same death rates of the general population (cure fractions) and those of prevalent patients who were not at risk of dying as a result of cancer (cure prevalence) were calculated, using validated mixture cure

Совпадение в полном тексте источника
… The general aim of the present study was to expand the spectrum of indicators of long-term survival and cure among cancer patients, in order to provide helpful information for epidemiologists and health-care planners, as well as for oncologists [ 9 ] and patients [ 7 ]. … In addition, for 26 cancer types (representing 95% and 97% of all cancer incidence in men and women, respectively), we estimated the time to reach the same death rates of the general population, which is of overwhelming importance for cancer patients and oncologists. …

Concurrent evolution of cancer cachexia and heart failure: bilateral effects exist.

Cancer cachexia is defined as a multifactorial syndrome of involuntary weight loss characterized by an ongoing loss of skeletal muscle mass and progressive functional impairment. It is postulated that cardiac dysfunction/atrophy parallels skeletal muscle atrophy in cancer cachexia. Cardiotoxic chemotherapy may additionally result in cardiac dysfunction and heart failure in some cancer patients. Heart failure thus may be a consequence of either ongoing cachexia or chemotherapy-induced cardiotoxicity; at the same time, heart failure can result in cachexia, especially muscle wasting. Therefore, t

Совпадение в полном тексте источника
… Oncologists have existing indications for cardiac investigation and follow up; however, these are restricted to investigational new drugs and drugs in current use that are cardiotoxic (Fig. 3 ). … Collaboration between medical oncologists and cardiologists is essential to develop this area [ 43 ]. We must develop a clearer idea of which cancer patients could benefit from cardiac therapies. …